Intercept Pharmaceuticals Inc.

18.15+0.2700+1.51%Vol 670.22K1Y Perf -1.49%
May 16th, 2022 16:00 DELAYED
BID18.05 ASK19.35
Open17.98 Previous Close18.15
Pre-Market- After-Market19.05
 - -  0.90 4.96%
Target Price
28.40 
Analyst Rating
Hold 2.60
Potential %
56.47 
Finscreener Ranking
★★+     47.78
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     43.33
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     49.47
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
60.87 
Earnings Rating
Strong Buy
Market Cap539.29M 
Earnings Date
6th May 2022
Alpha-0.03 Standard Deviation0.19
Beta1.27 

Today's Price Range

17.5719.30

52W Range

11.6022.36

5 Year PE Ratio Range

-5.20-4.70

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-3.30%
1 Month
10.20%
3 Months
17.48%
6 Months
2.43%
1 Year
-1.49%
3 Years
-79.00%
5 Years
-84.12%
10 Years
-

TickerPriceChg.Chg.%
ICPT18.150.27001.51
AAPL145.54-1.5700-1.07
GOOG2 295.85-34.4600-1.48
MSFT261.500.38000.15
XOM90.952.09002.35
WFC42.21-0.4300-1.01
JNJ178.081.23000.70
FB200.041.42000.71
GE74.63-0.4200-0.56
JPM118.26-0.8300-0.70
Financial StrengthValueIndustryS&P 500US Markets
2.90
3.20
0.91
10.45
-0.50
Leverage Ratio -2.30
ProfitabilityValueIndustryS&P 500US Markets
99.20
-6.00
-5.30
-142.20
-18.61
RevenueValueIndustryS&P 500US Markets
370.39M
12.47
20.19
40.50
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.89-0.5834.83
Q04 2021-1.26-1.232.38
Q03 2021-1.00-0.6337.00
Q02 2021-1.24-0.3373.39
Q01 2021-1.53-1.2220.26
Q04 2020-1.55-1.58-1.94
Q03 2020-1.96-2.01-2.55
Q02 2020-2.94-1.9234.69
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.5245.83Positive
9/2022 QR-0.7215.29Positive
12/2022 FY-2.716.87Positive
12/2023 FY-2.55-360.20Negative
Next Report Date-
Estimated EPS Next Report-0.89
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume670.22K
Shares Outstanding29.71K
Shares Float21.02M
Trades Count8.89K
Dollar Volume12.45M
Avg. Volume1.17M
Avg. Weekly Volume1.07M
Avg. Monthly Volume1.42M
Avg. Quarterly Volume1.02M

Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) stock closed at 18.15 per share at the end of the most recent trading day (a 1.51% change compared to the prior day closing price) with a volume of 670.22K shares and market capitalization of 539.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 498 people. Intercept Pharmaceuticals Inc. CEO is Jerome B. Durso.

The one-year performance of Intercept Pharmaceuticals Inc. stock is -1.49%, while year-to-date (YTD) performance is 11.42%. ICPT stock has a five-year performance of -84.12%. Its 52-week range is between 11.6 and 22.36, which gives ICPT stock a 52-week price range ratio of 60.87%

Intercept Pharmaceuticals Inc. currently has a PE ratio of -8.10, a price-to-book (PB) ratio of 52.34, a price-to-sale (PS) ratio of 1.46, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -13.73%, a ROC of -49.87% and a ROE of 24.36%. The company’s profit margin is -18.61%, its EBITDA margin is -5.30%, and its revenue ttm is $370.39 Million , which makes it $12.47 revenue per share.

Of the last four earnings reports from Intercept Pharmaceuticals Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.89 for the next earnings report. Intercept Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Intercept Pharmaceuticals Inc. is Hold (2.6), with a target price of $28.4, which is +56.47% compared to the current price. The earnings rating for Intercept Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Intercept Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Intercept Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.43, ATR14 : 1.31, CCI20 : 83.79, Chaikin Money Flow : 0.29, MACD : 0.44, Money Flow Index : 83.09, ROC : 14.15, RSI : 55.62, STOCH (14,3) : 63.65, STOCH RSI : 0.34, UO : 43.09, Williams %R : -36.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Intercept Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (20.00 %)
2 (20.00 %)
2 (18.18 %)
Moderate Buy
1 (10.00 %)
1 (10.00 %)
1 (9.09 %)
Hold
6 (60.00 %)
6 (60.00 %)
7 (63.64 %)
Moderate Sell
1 (10.00 %)
1 (10.00 %)
1 (9.09 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
2.60
Hold
2.60
Hold
2.64

Intercept Pharmaceuticals Inc.

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor.

CEO: Jerome B. Durso

Telephone: +1 646 747-1000

Address: 10 Hudson Yards, New York 10001, NY, US

Number of employees: 498

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

56%44%

TipRanks News for ICPT

Wed, 11 May 2022 16:49 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Agenus (AGEN), Intercept Pharma (ICPT) and PolyPid (PYPD)

- TipRanks. All rights reserved.

Mon, 09 May 2022 18:05 GMT Analysts Offer Insights on Healthcare Companies: Intercept Pharma (ICPT) and Amicus (FOLD)

- TipRanks. All rights reserved.

Sat, 07 May 2022 03:32 GMT Intercept Pharma (ICPT) Receives a Buy from Robert W. Baird

- TipRanks. All rights reserved.

Thu, 05 May 2022 15:05 GMT Analysts Offer Insights on Healthcare Companies: Autolus Therapeutics (AUTL), Intercept Pharma (ICPT) and Durect (DRRX)

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 17:25 GMT Intercept Pharma (ICPT) Gets a Buy Rating from B.Riley Financial

- TipRanks. All rights reserved.

Thu, 03 Mar 2022 12:36 GMT Analysts Conflicted on These Healthcare Names: Mesoblast (MESO), Intercept Pharma (ICPT) and Chimerix (CMRX)

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 19:10 GMT Intercept Pharma (ICPT) Receives a Hold from JMP Securities

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 01:50 GMT Intercept Pharma (ICPT) Gets a Hold Rating from RBC Capital

- TipRanks. All rights reserved.

News

Stocktwits